Three candidate antibodies—anti‐EpCAM, anti‐ASGPR, and anti‐GPC‐3—were selected to target these specific surface markers, aiming to achieve the desired sensitivity and specificity for HCC CTC identification. Here, EPCAM is linked to hepatocellular carcinoma.